Mercer Global Advisors’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.45M Buy
18,513
+7,212
+64% +$492K ﹤0.01% 1527
2026
Q1
$730K Buy
11,301
+205
+2% +$14.5K ﹤0.01% 1739
2025
Q4
$747K Sell
11,096
-666
-6% -$44.8K ﹤0.01% 1619
2025
Q3
$863K Buy
+11,762
New +$781K ﹤0.01% 1460
2024
Q3
Sell
-3,484
Closed -$209K 1993
2024
Q2
$209K Buy
+3,484
New +$153K ﹤0.01% 1782
2023
Q2
Sell
-9,517
Closed -$363K 1974
2023
Q1
$363K Sell
9,517
-3,988
-30% -$187K ﹤0.01% 1395
2022
Q4
$768K Sell
13,505
-3,131
-19% -$160K ﹤0.01% 1025
2022
Q3
$658K Sell
16,636
-2,259
-12% -$99.8K ﹤0.01% 1021
2022
Q2
$831K Buy
18,895
+2,071
+12% +$89.6K 0.01% 924
2022
Q1
$671K Sell
16,824
-31,788
-65% -$1.13M ﹤0.01% 1084
2021
Q4
$1.96M Buy
48,612
+337
+0.7% +$12.6K 0.01% 629
2021
Q3
$1.96M Buy
48,275
+10,900
+29% +$456K 0.01% 620
2021
Q2
$1.7M Buy
37,375
+1,003
+3% +$44.4K 0.01% 634
2021
Q1
$1.52M Buy
+36,372
New +$1.66M 0.01% 628

Other funds holding HALO

Mercer Global Advisors's HALO Position: Q2 2026 in Review

Mercer Global Advisors increased its Halozyme (HALO) stake by 64% in Q2 2026, buying an estimated $492K and bringing the position to 18,513 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1527.

Mercer Global Advisors first reported a position in HALO in Q1 2021 and has held it in 14 quarters since. The position peaked at $1.96M in Q3 2021. 672 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Mercer Global Advisors held 18,513 shares of Halozyme worth $1.45M as of Q2 2026.
  • Mercer Global Advisors bought 7,212 Halozyme shares in Q2 2026, an estimated $492K.
  • Halozyme made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #1527 holding.
  • Mercer Global Advisors first reported a position in Halozyme in Q1 2021 and has held it in 14 quarters since.
  • Mercer Global Advisors's Halozyme position peaked at $1.96M in Q3 2021.
  • 672 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.